ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $3,533,023 | +57.0% | 28,051 | +16.7% | 0.01% | +33.3% |
| Q3 2023 | $2,250,076 | +104.6% | 24,029 | +95.0% | 0.01% | +125.0% |
| Q2 2023 | $1,099,649 | -16.8% | 12,321 | -0.0% | 0.00% | -33.3% |
| Q1 2023 | $1,321,486 | -12.2% | 12,325 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $1,505,253 | +917.1% | 12,325 | +673.2% | 0.01% | +700.0% |
| Q2 2022 | $148,000 | +20.3% | 1,594 | +52.4% | 0.00% | 0.0% |
| Q1 2022 | $123,000 | +2975.0% | 1,046 | +3069.7% | 0.00% | – |
| Q4 2021 | $4,000 | -20.0% | 33 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | +25.0% | 33 | 0.0% | 0.00% | – |
| Q2 2021 | $4,000 | 0.0% | 33 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | -33.3% | 33 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 33 | 0.0% | 0.00% | – |
| Q3 2020 | $5,000 | – | 33 | +1000.0% | 0.00% | – |
| Q2 2020 | $0 | – | 3 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |